Tips

美迪西汇总整理了3月生物医药行业会议供参考交流。同时，我们将计划参与海内外8场会议：

IVC2024第四届核酸疫苗与创新疫苗研发工艺论坛

IVC2024第四届核酸疫苗与创新疫苗研发工艺论坛将于2024年3月1-2日在上海盛大召开：80余位专家学者，1000位行业同行邀您共襄盛会，2天3个会场全力打造疫苗盛宴。

2024（第四届）类器官大会

为推动国际类器官领域的发展，促进研究人员深入交流合作，探讨类器官研究领域的关键科学问题，2024（第四届）类器官大会—类器官与新药研发暨ISoOR 2024国际类器官高峰论坛将于2024年3月7-8日在中国上海雅居乐万豪侯爵酒店召开。

第七届成都生物医药创新者峰会

美迪西首席科学官彭双清教授将担任论坛主持嘉宾，毒理研究部高级主任邹汉军博士将出席GLP1药物开发论坛并发表主题演讲。

第七届成都生物医药创新者峰会将于2024年3月7-8日于成都举办，会议将涵盖ADC，改良型新药，小分子新药，GLP-1药物研发领域前沿动态，并聚焦最新临床进展。旨在打破行业的信息壁垒，推动创新多元发展！届时美迪西商务团队将在A01展位等候您的莅临。

第九届细胞生物产业大会

细胞生物产业作为战略性新兴产业，近年来不断获得政策的支持和市场的青睐。2023更是细胞生物领域取得重大突破的一年，发改委对外发布的《产业结构调整指导目录（2024年本）》，鼓励细胞产业的发展，预示着我国细胞生物产业正在与全球前沿接轨。细胞生物产业在2023年的表现，为市场环境重振了信心，也为更多的研究立项带来期待和转机。

于此背景下，第九届细胞生物产业大会暨第七届中国生物医药创新合作大会将于2024年3月8-9日在深圳盛大开幕！本次大会由深圳市细胞治疗技术协会、正和会展联合组织，助力细胞生物产业创新发展，合作共赢！

SOT 63rd Annual Meeting and ToxExpo

More Science, More Networking, More Everything in 2024

Medicilon is excited to attend and exhibit at the conference. Dr. Haizhou Zhang, president of preclinical R&D unit at Medicilon, will be available at the booth. Dr. Zhang holds a PhD in Toxicology from Indiana University, USA. He is a pharmaceutical industry veteran with over 20 years of experience in the R&D of small and large molecule drugs.

Medicilon's state-of-the-art preclinical facilities hold full AAALAC accreditation. With advanced platforms and experienced scientists, Medicilon guarantees the utmost professionalism in drug efficacy and safety assessments services, adhering to global regulatory standards. Offering services from stand-alone preclinical studies to comprehensive IND-enabling packages, Medicilon provides flexible solutions to efficiently support biotech and pharmaceutical clients in reaching their developmental milestones.

14th World ADC London

Europe's Longest Standing & Definitive Antibody-Drug Conjugate Event！

Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development.

In the formulation of ADC preclinical integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Medicilon started ADC non-clinical research in 2014. As of the end of 2023, We has successfully assisted in the clinical approval of 20+ ADC drugs by NMPA and/or FDA and has 30+ ADC projects under development.

2024 NEDMDG Spring Meeting

Recent interest in the delivery of therapeutics to the brain has dramatically increased with the advent of new ADCs and other targeted delivery vehicles for the treatment of dementias and glioblastoma. In addition, subcutaneous delivery has been found to be an effective mode of ADC delivery, but the bioavailability in humans has been difficult to predict. These two factors have driven an increasing interest in the human cell-based in vitro models for screening novel delivery methods to gain mechanistic insight into the factors that control either entry into the brain or systemic bioavailability of subcutaneously delivered drugs. In this presentation Dr. Roger Kamm will present the models specifically developed for both applications and the potential for iPS cell-derived systems. The benefits and current limitations of these models will also be addressed with the goal of stimulating an active discussion.

The Seminar is Sponsored by Medicilon.

IDC2024

从当前“创新”布局来看，内卷严重，靶点扎堆，同质化竞争激烈：内卷之中如何做到扶摇直上九万里而不被卷入旋涡，却成了创新药人当下最需要考虑的一点。

BIOCHINA2024(EBC)

美迪西新分子类型专场将于3月16日在大会期间举行，美迪西毒理研究部副总裁曾宪成博士与毒理研究部高级主任邹汉军博士受邀出席并发表主题演讲。

BIOCHINA2024第九届易贸生物产业展览(EBC)将于2024年3月14-16日在苏州国际博览中心ABCDEFG馆召开。

BIOCHINA2024(EBC)全新起航，以“展览-大会-活动”三大体系，规模30,000人、550家展商、500场学术报告。届时美迪西商务团队将在C3馆C060-C061展位等候您的莅临。

ACS Spring 2024

Many Flavors of Chemistry！

Founded in 1876 and chartered by the U.S. Congress, ACS is one of the world's largest scientific organizations with more than 200,000 individuals in its global community across 140 countries.

With the rapid development of the global pharmaceutical market and the division of labor in the industry, the process of drug discovery and development is becoming increasingly refined. This makes specialized outsourcing an important strategic choice for pharmaceutical companies. In the early stages, companies often use FTE models for the synthesis of structural fragments and candidate compounds to accelerate the drug screening process. Medicilon provides comprehensive chemistry research services covering all stages of your project requirements, and we offer cooperation through both FFS and FTE models.

2024美迪西创新药物产业生态合作大会

2004年，美迪西成立。

回首廿载，美迪西始终专注一站式临床前研发服务平台建设，与中国创新药企业携手同行，共同见证行业的发展与蜕变。

2024年，为进一步推动中国新药事业的高质量发展，美迪西创新药物产业生态合作大会将于2024年3月18日在上海举行。500余位行业精英共聚沪上，为创新药物产业生态建言献策，共同探索中国医药企业合作发展新机遇。

BIO-Europe Spring

Connecting the global biopharma community to elevate life science partnerships

BIO-Europe Spring, the premier springtime partnering event, brings together over 3,700 attendees from 2,000+ companies to engage in 20,000 one-to-one meetings.

Medicilon provides comprehensive one-stop R&D services for pharmaceutical enterprises and scientific research institutions around the world. Based on the key requirements of drug R&D, we focus on meeting the demand for innovation and development. With our experience in serving domestic and foreign biomedical industries, we have built an integrated platform covering key technologies in drug discovery, pharmaceutical research, and preclinical research, to provide a comprehensive preclinical R&D service for the global biomedical industry. By the end of 2023, we have served more than 2000 clients globally with more than 300 INDs approved in China and more than 80 INDs approved overseas.

SIT 2024第六届小分子药物创新与合作大会

本届大会内容将聚焦小分子药物的创新开发、立项策略、生产与MAH、转化医学、合作共赢、PROTAC、共价抑制剂、PPI、变构抑制剂、多肽偶联药物、多肽减重药物、 AI与CADD助力新药开发及其他新技术等，跨越小分子药物研发的热点领域，一览当下化学创新药研发新动向，致力于打破行业的封闭循环，破除行业内卷，助推创新多元发展!一切尽在小分子药物的年度产业大会!

SABPA Event

8th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum

SABPA FTD annually brings together the latest in groundbreaking research, cutting-edge drugs, and industry trends within the biopharma sector. The event's broad spectrum of topics provides a platform to engage in vibrant discussions and valuable networking opportunities. The forthcoming 8th FTD Conference is set to shine a spotlight on three revolutionary domains in the field of metabolism disease and oncology: GLP-1, ADC, and Minimal Residual Disease (MRD), each representing the forefront of innovations in therapeutics and diagnostics.

2024生物药创新与质量大会

生物药是目前最具投资价值的医药细分领域，在全球在研药物整体中的比例逐年上升。伴随国家各类医药政策的扶持和资本的孵化，中国生物医药创新迎来了新的历史机遇。

生物医药研发与创新相关技术的进步是生物医药产业发展的基础。为推动生物医药产业发展，更好地促进生物技术产学研交流，由中国食药促进会检验检定分会、四川省生物化学与分子生物学学会、四川省药学会药物分析专业委员会和四川省药学会生物药物专业委员会主办，药检汇联合主办，由杭州奇易科技有限公司承办的“BIQC2024生物药创新与质量大会”将于2024年3月在成都举行。大会以“创新引领高质量发展”为主题，搭建合作交流平台，聚焦国家发改委“十四五”生物经济发展规划，探讨新时代变革中生物医药产业发展的新思路、新路径。围绕mRNA疫苗、多肽药物、抗体偶联等前沿生物技术、生物药研发创新与质量控制展开深入交流和研讨。

第二届中国生物药分析与质量峰会

随着生物药技术的不断发展，药物的类型越来越多，我国的生物药研发与生产也进入到一个快速增长的时期。

生物药的分子量大、空间结构严格、修饰形式和变异体多样等特点，给药物分析与质量控制带来了巨大挑战。血清、血浆、唾液、尿液和组织等生物基质中药物浓度测定是药物研发的重要环节，科学的生物分析方法对于药物药代动力学、毒代动力学、生物等效性等药物的临床前研究提供依据。理化、杂质、生物学活性、免疫学特性及相关的表征研究等非常复杂，科学的质量管理与控制体系是生物药研发及生产重点关注与探讨的方向。生物药分析与质量峰会BioAQ是药物分析、质量及监管方面重要的交流平台，致力于促进生物医药行业产、学、研技术交流与合作。峰会围绕当下生物药发展趋势和监管要求，对单抗、双/多抗、重组/融合蛋白、细胞治疗、基因治疗、核酸药物等的生物分析方法与质量控制进行分享和深入探讨。

marketing@hangzhouaijunshengwu.com
微信或邮件hangzhouaijunshengwu.com